Genomic study points to new treatment approaches for advanced small-cell lung cancer
This study identified molecular changes in four subtypes of advanced SCLC. The findings could lead to the development of new targeted therapies for advanced SCLC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 26, 2021 Category: Cancer & Oncology Source Type: news
Drug testing approach uncovers effective combination for treating small cell lung cancer
(NIH/National Center for Advancing Translational Sciences (NCATS)) NIH researchers have identified and tested a drug combination that exploits a weakness in small cell lung cancer, an aggressive cancer. They targeted a vulnerability in cancer cell reproduction, increasing replication stress ¬ ¬ -- a hallmark of out-of-control cell growth in many cancers that damages DNA and forces cancer cells to constantly repair themselves. In a small trial, the drug duo shrank tumors in SCLC patients. The team's findings appear April 12 in Cancer Cell. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: news
A new treatment for metastatic lung cancer
(University of Colorado Anschutz Medical Campus) A new phase 3 randomized clinical trial overseen by CU Cancer Center member Chad Rusthoven, MD, and Vinai Gondi, MD, from Northwestern University, is testing whether a new treatment approach could result in improved outcomes for patients with small cell lung cancer (SCLC) that has spread to the brain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2021 Category: Cancer & Oncology Source Type: news
Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full details of the ...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news
Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full details of the ...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news
Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS in the ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news
Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS in the ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news
Pembrolizumab SCLC Indication Withdrawn in US Pembrolizumab SCLC Indication Withdrawn in US
The small cell lung cancer (SCLC) indication had been granted an accelerated approval, but a subsequent confirmatory study showed no survival benefit.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 4, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Four Small Cell Lung Cancer Subtypes and Their Best Therapies Four Small Cell Lung Cancer Subtypes and Their Best Therapies
Researchers identified four SCLC subtypes and proposed that matching baseline tumor subtypes to SCLC therapy may enhance the depth and duration of response.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
ASCO Endorses Guidelines on Radiation Therapy for SCLC ASCO Endorses Guidelines on Radiation Therapy for SCLC
The American Society of Clinical Oncology (ASCO) has endorsed guidelines on radiation therapy for patients with small cell lung cancer (SCLC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Durvalumab not cost effective for first-line treatment of advanced SCLC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news
Study defines small-cell lung cancer subtypes and distinct therapeutic vulnerabilities for each type
(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer (SCLC) into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type in a study published today in Cancer Cell. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 21, 2021 Category: International Medicine & Public Health Source Type: news
Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Ga...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Ga...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news
Oncotarget: NRXN1 as a novel potential target for small cell lung cancer
(Impact Journals LLC) The cover for issue 39 of Oncotarget features Figure 4, " Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves, " by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 30, 2020 Category: Cancer & Oncology Source Type: news
